Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

10(67%)

Results Posted

50%(1 trials)

Phase Distribution

Ph phase_3

13%

Ph phase_4

27%

Ph early_phase_1

Ph phase_1

13%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution15 total trials

Early Phase 1First-in-human

1(6.7%)

Phase 1Safety & dosage

2(13.3%)

Phase 2Efficacy & side effects

6(40.0%)

Phase 3Large-scale testing

2(13.3%)

Phase 4Post-market surveillance

4(26.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(10)

Completed(2)

Terminated(1)

Other(2)

Detailed Status

Recruiting9

Completed2

unknown2

Active, not recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (6.7%)

Phase 12 (13.3%)

Phase 26 (40.0%)

Phase 32 (13.3%)

Phase 44 (26.7%)

Trials by Status

recruiting960%

active_not_recruiting17%

completed213%

unknown213%

withdrawn17%

Recent Activity

10 active trials

Showing 5 of 15

recruitingphase_3

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

NCT05569772

recruitingphase_1

Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039

withdrawnphase_2

Tailoring Obesity Treatment Trial

NCT06619015

active_not_recruitingphase_2

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT05067621

recruitingphase_3

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

NCT05819138

View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials

NCT05569772Phase 3

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

Recruiting

NCT05746039Phase 1

Feasibility of Semaglutide in Advanced Lung Disease

Recruiting

NCT06619015Phase 2

Tailoring Obesity Treatment Trial

Withdrawn

NCT05067621Phase 2

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

Active Not Recruiting

NCT05819138Phase 3

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

Recruiting

NCT06852391Phase 4

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

Recruiting

NCT06548490Phase 2

GLP-1R Agonist Treatment for Opioid Use Disorder

Recruiting

NCT06908694Phase 4

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Recruiting

NCT05424003Phase 2

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

Recruiting

NCT05303857Phase 4

Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

Completed

NCT06411210Phase 2

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Recruiting

NCT05302596Phase 2

Semaglutide Use in Elderly Obese Patients

Completed

NCT06149260Phase 1

Subcutaneous Semaglutide in Systemic Scleroderma

Recruiting

NCT05870462Phase 4

Semaglutide and Vascular Regeneration

Unknown

NCT05249881Early Phase 1

"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

Unknown

All 15 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 15